Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Cullen Frost Bankers Inc.

Cullen Frost Bankers Inc. boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,000 shares of the medical research company’s stock after acquiring an additional 1,257 shares during the quarter. Cullen Frost Bankers Inc.’s holdings in Thermo Fisher Scientific were worth $14,862,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Raleigh Capital Management Inc. raised its holdings in Thermo Fisher Scientific by 49.1% during the third quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after purchasing an additional 27 shares in the last quarter. Cedar Mountain Advisors LLC raised its holdings in Thermo Fisher Scientific by 107.0% during the fourth quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock worth $47,000 after purchasing an additional 46 shares in the last quarter. Pacific Capital Wealth Advisors Inc. acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth approximately $51,000. Financial Connections Group Inc. acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth approximately $53,000. Finally, Operose Advisors LLC raised its holdings in Thermo Fisher Scientific by 250.0% during the third quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock worth $53,000 after purchasing an additional 75 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO traded up $0.77 during midday trading on Wednesday, hitting $573.64. 1,585,506 shares of the stock were exchanged, compared to its average volume of 1,549,346. The stock has a market cap of $218.97 billion, a P/E ratio of 36.80, a PEG ratio of 2.37 and a beta of 0.80. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82. The company has a 50 day moving average price of $575.72 and a 200-day moving average price of $535.12.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.70 by $0.41. The business had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 21.64 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were paid a $0.39 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s payout ratio is presently 10.01%.

Insider Activity at Thermo Fisher Scientific

In related news, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the transaction, the director now owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the transaction, the director now owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $564.72, for a total transaction of $5,647,200.00. Following the transaction, the chief executive officer now directly owns 128,485 shares of the company’s stock, valued at approximately $72,558,049.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 37,711 shares of company stock valued at $21,630,972. 0.34% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Evercore ISI lifted their target price on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Royal Bank of Canada lifted their target price on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Robert W. Baird cut their target price on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, April 25th. The Goldman Sachs Group lifted their target price on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday, April 25th. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $607.35.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.